1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsClinical Pharmacoepidemiology Training Grant is sponsored by NIH National Institute of General Medical Sciences. Postdoctoral training program focusing on clinical pharmacoepidemiology, including drug safety and comparative effectiveness research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Clinical Pharmacoepidemiology Training Grant - Sean Hennessy Clinical Pharmacoepidemiology Training Grant University of Pennsylvania, Philadelphia, PA, United States Search grants from University of Pennsylvania Mapping Molecular and Phenotypic Interactions in Alzheimers Disease In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy Saxs Study on the Cytoplasmic Subcomplex From the Vibrio Cholerae Type 2 Secreti Molecular Genetics of Gynecologic Cancers Kidney Disease and Hypertension in Blacks Shared Resource 13: Pharmaco Analytical (PhASR) Shared Resource 14: Proteomics (PSR) Shared Resource 15: Recruitment, Intervention, and Survey (RISSR) Shared Resource 16: Small Animal Imaging (SAISR) Democratization of Data Analysis in Life Sciences Through Galaxy The Center for Clinical Epidemiology and Biostatistics (CCEB) and the Center for Pharmacoepidemiology Research and Training (CPeRT) of the University of Pennsylvania (Penn) Perelman School of Medicine submit this renewal application to continue and expand our innovative and highly successful post-doctoral training program in clinical pharmacoepidemiology.
Pharmacoepidemiology is the study of the use and effects of medications and other medical products in populations. This training program attracts highly qualified trainees from across the nation.
This intensive two- to three-year intensive clinical research training program is designed to: 1) train clinicians to be rigorous and independent academic investigators able to formulate research questions and use a wide range of pharmacoepidemiologic approaches to answer those questions; 2) provide an understanding of the basic principles of clinical pharmacology; 3) provide intensive, supervised research experience with mentors in clinical pharmacoepidemiology and content-area mentors; and 4) strengthen the links between clinical epidemiology and clinical pharmacology.
Trainees matriculate in our highly-successful Master of Science in Clinical Epidemiology (MSCE) degree program, and complete required courses in clinical epidemiology, pharmacoepidemiology research methods, outcome measurement, biostatistics, database management, pharmacokinetics; elective courses in drug development, pharmacology and other areas relevant to the trainees' interests and experience; independent readings; participation in research seminars at the CCEB and CPeRT; and the completion of a mentored independent research project of the trainee's design.
Given the high demand for slots in this program, we propose to expand this program to support five fellows per year.
Strengths of the proposed program include: 1) the large pool of highly qualified candidates with clinical training seeking rigorous research training in pharmacoepidemiology; 2) the long history of successful research training programs in the CCEB, including in pharmacoepidemiology and comparative effectiveness research / patient centered outcomes research; 3) the comprehensive course offerings and research programs available to trainees; and 4) the successful training record of the program director and other faculty.
In addition, the availability of the CCEB and CPeRT faculty, who provide expertise in a wide range of methodologic and clinical disciplines; numerous epidemiologic databases useful for research projects and training; a broad array of specialized analytic capabilities available for clinical studies (e.g., clinical trials, case-contrl, cohort, self- controlled designs, etc.); and the faculty members' commitment to collaborative research and training, combine to provide an ideal environment for this program.
There is a major national shortage of qualified clinicians able to conduct rigorous research in clinical pharmacoepidemiology. There is a particular shortage of clinical investigators focusing on drug safety and comparative effectiveness research / patient centered outcomes research.
This training program addresses this shortage by providing rigorous didactic training and mentored research performed in collaboration with outstanding program faculty.
Agency National Institute of Health (NIH) Institute National Institute of General Medical Sciences (NIGMS) Type Institutional National Research Service Award (T32) Project # 5T32GM075766-15 Study Section Special Emphasis Panel (ZGM1) Program Officer Garcia, Martha Name University of Pennsylvania Department Biostatistics & Other Math Sci Vajravelu, Ravy K; Mamtani, Ronac; Scott, Frank I et al.
(2018) Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. Gastroenterology 155:1416-1427 Miano, Todd A; Lautenbach, Ebbing; Wilson, F Perry et al. (2018) Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.
Clin J Am Soc Nephrol 13:542-550 Elgarten, Caitlin W; Arnold, Danielle E; Bunin, Nancy J et al. (2018) Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatr Blood Cancer 65: Miano, Todd A; Cuker, Adam; Christie, Jason D et al.
(2018) Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury. Chest 153:133-142 Elgarten, Caitlin W; Arnold, Staci D; Li, Yimei et al. (2018) Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation.
Infect Control Hosp Epidemiol 39:797-805 Noe, Megan H; Gelfand, Joel M (2018) Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology. J Invest Dermatol 138:e13-e18 Zhao, Yongdong; Wu, Eveline Y; Oliver, Melissa S et al. (2018) Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.
Arthritis Care Res (Hoboken) 70:1228-1237 Ogdie, Alexis; Kay McGill, Neilia; Shin, Daniel B et al. (2018) Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 39:3608-3614 Noe, Megan H; Rodriguez, Olaf; Taylor, Laura et al.
(2017) High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 34:136-141 Noe, M H; Grewal, S K; Shin, D B et al. (2017) Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom.
J Eur Acad Dermatol Venereol 31:1674-1680 Showing the most recent 10 out of 70 publications Be the first to comment on Sean Hennessy's grant
According to the current listing, eligibility includes: Postdoctoral clinicians in clinical pharmacoepidemiology. Confirm the full requirements in the official notice before applying.
Clinical Pharmacoepidemiology Training Grant is funded by NIH National Institute of General Medical Sciences. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read article